Xilio Therapeutics announces Roche collaboration for XTX101 in MSS CRC; cash $75.4M

Xilio Therapeutics, Inc.

Entered clinical trial collaboration with Roche; Xilio retains rights to XTX101; eligible for cost-sharing payments.
Updated XTX101 data: durable partial response 36 wks in NSCLC; no Grade 4/5 AEs at RP2D; no colitis.
XTX202 cleared 2.8 mg/kg dose, no vascular leak; expects preliminary Phase 1/2 data early Nov 2023 in ≥20 evaluable pts.
Q2 net loss $19.4M vs $24.6M YoY; cash $75.4M, runway into Q2 2024.
Promoted Chris Frankenfield to COO; XTX301 safety data expected Q4 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Xilio Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 14, 2023, Xilio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023 and other business highlights.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Xilio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-014708

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.